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Local Experience in the Treatment of Acute
Non-Lymphoblastic Leukaemia




Seventy-six patients suffering from various forms of acute
non-lymphoblastic leukaemia were seen at the Johannes-
burg Hospital over an 8-year period. During this time
various forms of therapy were used. Results with 6-mer-
captopurine and prednisone were very poor, with less than
10% of patients achieving complete remission. Dauno-
rubicin, when used alone, proved too toxic, but when
given in a smaller dose with other agents, was more
effective. The best results were obtained in 22 patients
in whom a combination of daunorubicin and cytosine
arabinoside was used. Complete remissions occurred in
9 patients and partial remissions in 2. The median sur-
vival of these 11 patients was 42 weeks. It is noteworthy
that 3 of these patients were still alive one-and-a-half
years from the time of diagnosis, and 1 of them is still
in complete remission, two years after she was first
treated.
S. Afr. Med. J., 48, 963 (1974).
Real progress in the drug treatment of acute leukaemia
has been made since Farber et al.! demonstrated that the
course of the disease could be modified by aminopterin.
Several points emerge from the many subsequent studies.
Firstly it is apparent that although remissions can be
achieved with single agents, this only occurs in a minority
of patients. For example, when 6·mercaptopurine was used
to treat acute myeloid leukaemia, remission rates varied
between 10 and 14%.',3 Results have been significantly
better when two or more agents are used together, and
recent trials using combinations of daunorubicin and
cytosine arabinoside or daunorubicin and thioguanine in
patients with acute myeloid leukaemia, reported initial
remission rates of about 50%, with significant prolonga-
tion of survival. ',' Even more striking results were obtained
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in the acute lymphatic leukaemia that occurs in childhood.
With a combination of vincristine and prednisone, initial
remission rates in excess of 80~~ are obtained: In addition
it is clear that prolonged remissions can be maintained in
a significant proportion of such patients if various types
of chemotherapy are continued after the induction of
the initial remission.'
Most of the results reported in the literature were ob·
tained in units with special expertise in the management of
acute leukaemia. While there has been a growing interest
in the subject at the Johannesburg Hospital over the past
several years, adult patients suffering from acute leukaemia
are treated in the general medical wards. The present article
records the findings in a retrospective analysis of the
results obtained during an 8-year period.
MATERIAL AND METHODS
Clinical Material
The clinical course and duration of survival of 87
patients with acute leukaemia were analysed retrospec-
tively. All the patients had been seen at the Haematology
Clinic of the Johannesburg General Hospital between
1965 and 1972. There was a steady build-up in the
number of patients seen; only I patient in 1965 compared
with 27 in 1972.
Seventy-six patients were suffering from some form
of acute non·lymphoblastic leukaemia, the cytological
diagnoses being: acute myeloblastic 39, acute myelomono-
cytic 18, erythroleukaemia 5, unspecified 4, leukaemia
aplasticus 4, acute promyelocytic 3, and acute blastic crisis
of chronic myeloid 3.
A cytological diagnosis of acute lymphoblastic leu-
kaemia was made in the remaining 11 patients. This
group included not only White adults but Black
children. It was felt that further analysis of these 11
patients would not be contributory since the group was
small and heterogeneous, and follow-up in the Black
children was difficult, since several of them had been
treated previously in other centres. The data that follow,
therefore, refer only to the 76 patients with acute non-
lymphoblastic leukaemia.
Therapeutic Regimens
A total of 59 patients received therapy, which was
considered to be adequate for evaluation of its effects.
In a further 7 patients a decision was made not
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to give specific chemotherapy. They were either suffering
from leukaemia aplasticus or had another severe chronic
illness in addition to the leukaemia. Finally, there were
10 patients who died too early during the course of
treatment for a proper evaluation to be made.
A combination of 6-mercaptopurine and prednisone
was used as the initial therapy in 15 patients treated
between 1965 and 1968. The dosage of 6-mercaptopurine
varied between 1,5 and 2.5 mgjkgjday, and that of
prednisone was 50 mg(day.
Seven patients were treated intravenously with dauno-
rubicin in a dosage of 1 mgjkgjday for 5 days.'
Additional courses of this therapy were given at 2- to 3-
week intervals.
Ten patients were treated with a 4-drug regimen. It
consisted of a combination of intravenous daunorubicin
0,75 mgjkg on day 1, oral 6-mercaptopurine 2,5 mgjkg
daily for 5 days, intravenous cytosine arabinoside 3
mgjkg for 3 days and 40 mg oral prednisone daily for
7 days.
Twenty-two patients received therapy with a combi-
nation of intravenous daunorubicin 1,5 mgjkg on day 1,
together with cytosine arabinoside 2 mgjkg daily for 5
days. The cytosine arabinoside was given intravenously
as a push-in every 12 hours. The treatment schedule was
repeated after intervals usually varying between 5 and
10 days.
Five patients received therapy with a 3-drug combination
consisting of vincristine 1,4 mgjm', daunorubicin 1 mgjkg
on day 1 and cytosine arabinoside 2 mgjkg daily for 3
days." If blast forms persisted in the marrow, the same
cycle of chemotherapy was repeated after an interval of
1 - 3 days.
Three patients seen before 1968 received miscellaneous
forms of therapy and in a further 4 subjects more than
one therapeutic regimen was used in an attempt to induce
a remission.
Supportive Care
Vigorous measures were taken to prevent the develop-
ment of hyperuricaemia; these included allopurinol, hy-
dration and urinary alkalinisation. Blood transfusions
were administered as required. The general aim was to
keep the haemoglobin level above 10 gj100 ml. Platelet
transfusions were given to patients with severe thrombo-
cytopenia only when active bleeding occurred.
Although the patients were not nursed in a sterile
environment, attempts were made to separate them from
the other patients in the ward. Prophylactic systemic anti-
biotic therapy was not used. All pyrexial episodes lasting
for more than 12 - 24 hours were treated initially as
bacterial infections by using a combination of bactericidal
antibiotics; therapy was changed appropriately when the
results of cultures came to hand.
From 1971 onwards oral non-absorbable antibiotics,
such as neomycin and kanamycin, were administered to
all patients and the diet was limited to cooked foods.
This was done in an attempt to limit bacterial growth
in the bowel. In addition, oral non-absorbable antifungal
agents were used as a routine.
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RESULTS
The criteria used for assessing whether a patient had
achieved a complete or partial remission were those
applied by the Acute Leukaemia Group B and others."
Early Deaths
It was impossible to evaluate 10 patients who died
before completion of the first course of therapy. The mean
duration of survival from the time of admission was 11
days, and death was caused by bleeding or infection, or
both.
No Specific Therapy
The clinical course followed by the 4 subjects with the
aplastic form of acute leukaemia was more like that of
aplastic anaemia than acute leukaemia. They required
supportive therapy with blood and platelet transfusions,
and antibiotics for recurrent episodes of infection. The
median duration of survival from the time of diagnosis
was 22 weeks.
Specific Therapeutic Regimens (Table I)
Results with single-agent treatment were poor. The
complete remission rate was only 7% with 6-mercapto-
purine and 14% with daunorubicin. While it was also poor
with a 4-drug combination of daunorubicin, cytosine
arabinoside, prednisone and 6-mercaptopurine, a further
30% achieved partial remission on this treatment. Com-
parable results were obtained by using a combination of
vincristine, daunorubicin and cytosine arabinoside.
The largest treatment group of 22 patients received
cycles of daunorubicin and cytosine arabinoside. The
complete remission rate was 31,5% and the partial remis-
sion rate 9%. The median survival was 19 weeks, and
similar to that in the patients on the 4-drug regimen;
median survival rates were less than 10 weeks in the other
two groups (Fig. 1).
Further analysis shows that the median survival rate
was significantly better (P<0,05) in the subjects who
responded to daunorubicin and cytosine arabinoside, than
in the group as a whole (42 weeks compared with 19
weeks). .
Maintenance therapy was given to most subjects who
achieved a remission with the initial treatment. In general,
the inducing drugs were administered at intervals in a
cyclical fashion. In addition, daily 6-mercaptopurine or
6-thioguanine and weekly methotrexate were given orally
to the majority of subjects. The individual patterns of
maintenance therapy administered to the 22 patients who
were initially treated with daunorubicin and cytosine
arabinoside, give a good reflection of the approach that
was generally followed (Fig. 2). When haematological
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leucocyte platelet Partial Complete
No. of Mean age Mean Hb count count remission remission
patients (years) (g/100 ml) (per mm') (per mm') (0/0) (%)
15 46 8,2 21 300 73000 7 7
7 43 9.6 32900 58000 14 14
10 56 9,6 24300 100000 30 10
22 43 9,1 24500 67000 9 31
5 36 11,0 8200 85000 20 20
• Daunorubicin 7 weeks (7 patients)
t::. 6 MP t Prednisone 9.5 weeks (15 patients)
0 Daunorubicin + Cytosine 19 weeks (22 patients)
• Daunorubicin + Cytosine + 6 MP + Prednisone




Daunorubicin + cytosine arabi-
noside + prednisone + 6-
mercaptopurine
Daunorubicin + cytosine arabi-
noside














Fig. 1. Cumulative survival curves for patients receiving 4 different drug regimens as primary induction therapy.
relapse occurred, reinduction was usually attempted with
the same agents that had been used for the initial
remission induction.
Factors Affecting Prognosis
An unsuccessful attempt was made to find out whether
it was possible to retrospectively predict the patients who
went into remission on chemotherapy. It did not appear
to depend on the patient's age, nor on the concentrations
of haemoglobin, white cells or platelets. It was noted, how-
ever, that the mean age (62 years) of the group which
received no therapy was older than that of the subjects
who did receive treatment. The mean white cell count was
lower in this group, but this was owing to the fact that
several of these patients were suffering from the aplastic
form of leukaemia.
Complications of Therapy
Minor complications of treatment, such as nausea and
vomiting, were troublesome in the majority of patients.
More serious was the haematological suppression induced
by the cytostatic agents. The lowest mean post-treatment
white cell count of 930/mm' was found in the patients
treated with daunorubicin alone. This figure was signifi-
cantly lower (P<0,05) than the mean figure of 2060/mm'
occurring with the 4-drug regimen and the mean figure
of 1 580/mm' in the patients treated with daunorubicin
and cytosine arabinoside. Similarly, the mean platelet count
(10000/mm') after treatment with daunorubicin alone was
significantly lower (P<0,05) than that after other forms of
treatment.
Cardiac complications which were ascribed to the use
of daunorubicin, occurred in 3 patients. One patient died
as a result of this complication. He had received a total
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voltages. She responded to a regimen of strict bedrest
and conventional antifailure therapy. A year later the
cardiac status was virtually normal.
Fig. 2. The treatment schedules used as maintenance and reinduction therapy in
22 patients initially treated with daunorubicin and cytosine arabinoside. The
periods which each patient spent in complete remission, partial remission and
relapse are indicated. The majority of patients received most of their therapy
on an outpatient basis.
dose of 37 mg/kg body mass over a period of more than
2 years. He complained of dyspnoea and tiredness and
on examination was found to have a low systolic blood
pressure, a small pulse volume, ~inus tachycardia, pro-
minent third and fourth heart sound gallops, and other
evidence of biventricular cardiac failure. These findings
were accompanied by a diminution of the QRS voltages
in all 12 leads of the standard electrocardiogram and T-
wave inversion over the left chest leads. No further At the time of this analysis 68 of the patients had died.
daunorubicin was given but the cardiac ~tatus continued In 52 subjects this was the result of bleeding or infection,
to deteriorate over several months. As a terminal event or both. Infection was the sole cause of death in 10
the patient developed complete atrioventricular dissociation, patients, and bleeding in a further 2. Death was ascribed
with a low cardiac output, which failed to respond to the to cardiac causes in 4 instances. As mentioned previously.
administration of inotropic agents or to transvenous daunorubicin was thought to be responsible in one
ventricular pacing. instance. This patient died while in complete remission.
A second patient, who was asymptomatic, developed • The other 3 cardiac deaths occurred while the patients
were in relapse.electrocardiographic changes; the~e consisted of diminution
of the QRS voltage and T-wave inversion. Daunorubicin In only 24 of the fatal infections was the responsible
wa stopped and the ECG returned to normal over a organism isolated. Pseudomonas septicaemia, which
period of 3 months. The third patient dev<.;loped the occurred in 7 patients, was the most commonly documented
clinical features of a congestive cardiomyopathy with infection. Escherichia coli was isolated in 6 patients, while
biventricular failure, enlargement of the cardiac silhouette fungal septicaemia, usually Candida albicans, occurred in
on X-ray examination, and diminished electrocardiographic a further 6.
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DISCUSSION
The therapeutic regimens used in the treatment of acute
non-lymphoblastic leukaemia have improved significantly
over the past few years.' This is to some degree reflected
in the present experience. Initially a combination of
6-mercaptopurine and prednimne was given, and the
results were almost uniformly poor. Daunorubicin, when
used as a single agent, proved too toxic and was quickly
abandoned. However, when administered in smaller doses
in combination with cytosine arabinoside; better results
were obtained, with a complete remission rate of 31 %
and significantly prolonged survival.
The question arises as to how such results measure up
to tho:e obtained by others. The. remission induction
rate in acute non-lymphoblastic leukaemia has been low
in several series reported by the Acute Leukaemia Group
B. In addition, Wilkinson and co-workers" recently
reported a median survival time of only 2 months in
115 patients treated with either single-agent or combi-
nation chemotherapy. In another series using POMP
(nitrogen mustard, vincriH;ne, methotrexate and predni-
sone) Rodriques and co-workers" obtained a complete
remission rate of 28 00, with a median survival of 28 weeks.
Better results have been obtained with a combination
of cytosine arabinoside and thioguanine, with complete
remission rates varying between 39% and 65 %.,,13,15 Worth-
\'/hile result; have also been obtained with cytosine
arabinoside and daunorubicin. Crowther et al: obtained
a complete remission rate of 49% in 94 patients. Com-
parable results have been reported by Rosenthal and
Moloney using a combination of vincristine, cytosine
arabinoside and daunorubicin, by Whitecar et al." using
COAP (cyclophosphamide, vincristine, cytosine arabino-
side and prednisone), and by Paolino et al." employing
'the latest MRC protocol, TRAP (thioguanine, dauno-
rubicin, cytosine arabinoside and prednisone).
All this evidence taken together suggests that with cur-
rently available drugs it is possible to induce complete
remission in between a third and a half of patients with
acute non-lymphoblastic leukaemia. While this represents
a significant therapeutic advance, the situation is still far
from satisfactory.
There appear to be ~everal reasons for the high failure
rate. Firstly a number of patients succumb to over-
whelming infection or to thrombocytopenic bleeding
before the chemotherapeutic agents have had time to
exert their effects. Attempt; to induce remission are further
complicat~d by the fact that none of the available drugs
are sufficiently selective in killing the leukaemic cell popula-
tion." This means that severe marrow depression occurs
as an inevitable sequela of effective chemotherapy. This
lack of drug specificity not only bedevils the problems
associated with remission induction but also hinders the
consolidation of such remissions when they do occur.
As a result, remissions tend to be of short duration, even
when maintenance chemotherapy is given. Until better
drugs become available other approaches will have to be
tried. In this context, both specific and non-specific
immunotherapy have been advocated as a means of attack-
ing the small residual leukaemic population that remains
during periods of remission.'
With a disease that is still almost uniformly fatal it
is appropriate to ask whether the present aggressive
therapeutic regimens are justifiable. Any team of doctors
caring for such patients certainly has moments when the
cumulative emotional drain impairs morale and judge·
ment. But they do not last. The median survival rates do
not adequately portray the quality of that survival. The
majority of patients achieving complete or even partial
remission enjoy good health for most of the survival
period. In addition, it is po~sible in most to give later
courses of therapy (Fig. 2) on an outpatient basis.
This means that many continue working and enjoy a
normal family life until very late in the course of the
disease.
There is another reason for the pre:ent attitude-it is
not yet possible to predict who will respond or how lone
that response will last. In each large group of sufferer~
there are thus individuals who will go into remission
promptly on appropriate therapy, and who will continue
in good health for months and even years. While the
dividend is small, it is nevertheless very worth while.
One final point warrants stressing. The handling of
patients with acute leukaemia requires considerable ex-
pertise, not only in terms of the medical management,
but concerning the patients' emotional problems. The
drugs used are extremely toxic and even when recoonised
regimens are followed, dosage and spacing of trea~ment
often require modification. In addition, the handling of
patients whose bone marrow has been seriously com--
promised by therapy, poses its own special problems.
Difficulties are compounded by the many personal prob-
lems faced by the patient. Th,;, confidence required to
manage these many facets comes only with experience,
making it essential that patients are referred for treat-
ment to recognised centres that have the necessary
facilities.
Professor Bothwell was in receipt of a grant from the
South African Medical Research Council and the Atomic
Energy Board.
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